Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor

Table 1 Patient characteristics

Patient categories	Number of Patients	Eligible Patients
		HR	CR	Total
Registered in GIPAP	106	74	29	103
Diagnosed in Patan	29	16	12	28
Diagnosed at Other Hospitals	77	58	17	75
Excluded	3	0	0	0
Chronic Phase	98	69	27	96
Accelerated Phase	5	5	0	5
Blast Crisis	3	0	2	2
Male/Female	70/36	51/23	17/12	68/35
Follow up (Mean/Median) (m)	27/24	23/19	39/42	27/24
Age (mean/median)	39/39	39/40	38/38	39/39
Lost to f/u	8	8	0	8
Mortality	2	2	0	2

ISSN: 2052-1839